The 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis – 24-26 September 2025
The following summarizes some of the highlights from Day 1 of ECTRIMS 2025.
Latest News
ECTRIMS 2025 survey
September 4, 2025NeuroSens will be providing daily coverage of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2025 annual meeting, to be held September 24-26 in Barcelona, Spain. Read More
Baseline sNfL prognostic of disease activity in CIS
August 21, 2025Higher baseline levels of serum neurofilament-light chain (sNfL) are prognostic of disease activity in patients with clinically isolated syndrome, according to a retrospective analysis of 181 individuals presenting with CIS at two MS centres in Spain during the period 2004-2022 (Comabella et al. Neurol Neuroimmunol Neuroinflamm 2025;12:e200370). Read More
CLINICAL CASES IN MS: A PATIENT CONSIDERING TREATMENT DISCONTINUATION
August 19, 2025P.B. is a 57-year-old woman with a 24-year history of relapsing-remitting multiple sclerosis. She was treated with an injectable from 2002-2012. Her last relapse was in 2009. She was transitioned to fingolimod in 2012 because of ongoing MRI changes and increasing tolerability issues. Read More